Elizabeth Bilsland

Prof. Dr. Elizabeth Bilsland

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2004 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
EBElizabeth Bilsland
Elizabeth Bilsland
CMClaes Molin
Claes Molin
SSSwarna Swaminathan
Swarna Swaminathan
ARAnna Ramne
Anna Ramne
PSPer Sunnerhagen
Per Sunnerhagen
Summary: We demonstrate a role in oxidative and metal stress resistance for the MAPK‐activated protein kinases Rck1 and Rck2 inSaccharomyces cerevisiae. We show that Hog1 is robustly phosphorylated in a Pbs2‐dependent way during oxidative stress, and that Rck2 also is phosphorylated under these circumstances. Hog1 concentrates in the nucleus in oxidative stress. Hog1 localization is partially dependent on Rck2, asrck2cells have more nuclear Hog1 than wild‐type cells. We find several proteins with a role in oxidative stress resistance using Rck1 or Rck2 as baits in a two‐hybrid screen. We identify the transcription factor Yap2 as a putative target for Rck1, and the Zn2+transporter Zrc1 as a target for Rck2. Yap2 is normally cytoplasmic, but rapidly migrates to the nucleus upon exposure to oxidative stress agents. In a fraction of untreatedpbs2cells, Yap2 is nuclear. Zrc1 co‐immunoprecipitates with Rck2, andZRC1is genetically downstream ofRCK2. These data connect activation of the Hog1 MAPK cascade with effectors having a role in oxidative stress resistance.

6 March 2015 in Journal of The Royal Society Interface
Verified
Journal Article
Open access
KWKevin Williams
Kevin Williams
EBElizabeth Bilsland
Elizabeth Bilsland
ASAndrew Sparkes
Andrew Sparkes
WAWayne Aubrey
Wayne Aubrey
MYMichael Young
Michael Young
RKRoss D. King
Ross D. King
There is an urgent need to make drug discovery cheaper and faster. This will enable the development of treatments for diseases currently neglected for economic reasons, such as tropical and orphan diseases, and generally increase the supply of new drugs. Here, we report the Robot Scientist ‘Eve’ designed to make drug discovery more economical. A Robot Scientist is a laboratory automation system that uses artificial intelligence (AI) techniques to discover scientific knowledge through cycles of experimentation. Eve integrates and automates library-screening, hit-confirmation, and lead generation through cycles of quantitative structure activity relationship learning and testing. Using econometric modelling we demonstrate that the use of AI to select compounds economically outperforms standard drug screening. For further efficiency Eve uses a standardized form of assay to compute Boolean functions of compound properties. These assays can be quickly and cheaply engineered using synthetic biology, enabling more targets to be assayed for a given budget. Eve has repositioned several drugs against specific targets in parasites that cause tropical diseases. One validated discovery is that the anti-cancer compound TNP-470 is a potent inhibitor of dihydrofolate reductase from the malaria-causing parasite Plasmodium vivax .

1 March 2013 in Drug Discovery Today
Verified
Journal Article
Closed access
DKDouglas Kell
Douglas Kell
PDPaul D. Dobson
Paul D. Dobson
EBElizabeth Bilsland
Elizabeth Bilsland
SOStephen G. Oliver
Stephen G. Oliver

24 October 2011 in BMC Biology
Verified
Journal Article
Open access
PDF file
KLKarin Lanthaler
Karin Lanthaler
EBElizabeth Bilsland
Elizabeth Bilsland
PDPaul D Dobson
Paul D Dobson
HMHarry J Moss
Harry J Moss
PPPınar Pir
Pınar Pir
SOStephen Oliver
Stephen Oliver
Background: The uptake of drugs into cells has traditionally been considered to be predominantly via passive diffusion through the bilayer portion of the cell membrane. The recent recognition that drug uptake is mostly carrier-mediated raises the question of which drugs use which carriers. Results: To answer this, we have constructed a chemical genomics platform built upon the yeast gene deletion collection, using competition experiments in batch fermenters and robotic automation of cytotoxicity screens, including protection by 'natural' substrates. Using these, we tested 26 different drugs and identified the carriers required for 18 of the drugs to gain entry into yeast cells. Conclusions: As well as providing a useful platform technology, these results further substantiate the notion that the cellular uptake of pharmaceutical drugs normally occurs via carrier-mediated transport and indicates that establishing the identity and tissue distribution of such carriers should be a major consideration in the design of safe and effective drugs.

18 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EBElizabeth Bilsland
Elizabeth Bilsland
LVLiisa van Vliet
Liisa van Vliet
KWKevin Williams
Kevin Williams
JFJack Feltham
Jack Feltham
MCMarta P. Carrasco
Marta P. Carrasco
SOStephen Oliver
Stephen Oliver
Malaria, caused by parasites of the genus Plasmodium, leads to over half a million deaths per year, 90% of which are caused by Plasmodium falciparum. P. vivax usually causes milder forms of malaria; however, P. vivax can remain dormant in the livers of infected patients for weeks or years before re-emerging in a new bout of the disease. The only drugs available that target all stages of the parasite can lead to severe side effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; hence, there is an urgent need to develop new drugs active against blood and liver stages of the parasite. Different groups have demonstrated that triclosan, a common antibacterial agent, targets the Plasmodium liver enzyme enoyl reductase. Here, we provide 4 independent lines of evidence demonstrating that triclosan specifically targets both wild-type and pyrimethamine-resistant P. falciparum and P. vivax dihydrofolate reductases, classic targets for the blood stage of the parasite. This makes triclosan an exciting candidate for further development as a dual specificity antimalarial, which could target both liver and blood stages of the parasite.

1 February 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MCMonika Chugh
Monika Chugh
CSChristian Scheurer
Christian Scheurer
SSSibylle Sax
Sibylle Sax
EBElizabeth Bilsland
Elizabeth Bilsland
DSDonelly A. van Schalkwyk
Donelly A. van Schalkwyk
XDXavier Ding
Xavier Ding
Plasmodium falciparum , the most deadly agent of malaria, displays a wide variety of resistance mechanisms in the field. The ability of antimalarial compounds in development to overcome these must therefore be carefully evaluated to ensure uncompromised activity against real-life parasites. We report here on the selection and phenotypic as well as genotypic characterization of a panel of sensitive and multidrug-resistant P. falciparum strains that can be used to optimally identify and deconvolute the cross-resistance signals from an extended panel of investigational antimalarials. As a case study, the effectiveness of the selected panel of strains was demonstrated using the 1,2,4-oxadiazole series, a newly identified antimalarial series of compounds with in vitro activity against P. falciparum at nanomolar concentrations. This series of compounds was to be found inactive against several multidrug-resistant strains, and the deconvolution of this signal implicated pfcrt , the genetic determinant of chloroquine resistance. Targeted mode-of-action studies further suggested that this new chemical series might act as falcipain 2 inhibitors, substantiating the suggestion that these compounds have a site of action similar to that of chloroquine but a distinct mode of action. New antimalarials must overcome existing resistance and, ideally, prevent its de novo appearance. The panel of strains reported here, which includes recently collected as well as standard laboratory-adapted field isolates, is able to efficiently detect and precisely characterize cross-resistance and, as such, can contribute to the faster development of new, effective antimalarial drugs.